The data collected from 11 volunteer subjects (10 smokers and 1 subject who consumed THC infused edibles) showed similar results to those achieved during past green lab studies. The baseline (prior to consumption) delta9-THC breath concentrations were in most cases very low indicating no recent use of cannabis products. Thirty (30) minutes after observed consumption, the delta9-THC concentrations in breath per cartridge increased significantly – with the highest recorded values being around 25 ng/cartridge. After 60 minutes the THC concentrations in breath decreased but remained above baseline values. Subjects were then asked to re-dose after approximately 80 minutes after first cannabis consumption and analysis showed elevated levels of delta9-THC in breath in later time points, after re-dosing, even when compared to the levels observed after initial consumption.
Samples were analysed roughly 48 hours after collection and no obvious adverse effects related to storing or shipping were observed during the analysis process. The calibration curve acquired prior to analysing samples at the NLCL lab was similar to those used at the Company’s
The Company’s handheld Breath Collection Unit (“BCU”) (Fig. 3) and newly developed laboratory “MS Breath Sampler” (Fig. 4) are being used together to provide a new method for drug detection that complements gold-standard mass spectrometry (MS) and significantly simplifies laboratory analysis methods, reduces sample turnaround times (thus minimizing operating costs), while maintaining sensitive, precise results. By comparison, existing and legacy breath and saliva testing procedures require several sample extraction and preparation steps prior to analysis, and analysis itself can take from 1-3 hours per sample. This is expensive and impractical. Also, existing and legacy breath and saliva testing procedures tend to have inefficient, time-consuming collection methods, and recoveries are still often poor.
Fig. 1
Fig. 2 Cannabix MSBS at
Fig. 3
Fig. 4
About
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that its development of breathalyzer technologies will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. The is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies. There is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/0f334b58-6fb9-49d2-91db-65faa8366907
https://www.globenewswire.com/NewsRoom/AttachmentNg/96da6280-2610-4b02-a571-85ab685f678e
https://www.globenewswire.com/NewsRoom/AttachmentNg/efff9ab7-c692-456a-a52c-af7d9e7038bd
https://www.globenewswire.com/NewsRoom/AttachmentNg/c51f93f3-b026-4150-9ec7-dd8569c1b0b8
Cannabix Technologies Inc.
Fig. 1 Cannabix at North Louisiana Crime Lab
Cannabix Technologies Inc.
Fig. 2 Cannabix MSBS at North Louisiana Crime Lab
Cannabix Technologies Inc.
Fig. 3 Cannabix updated Breath Collection Unit (BCU)
Cannabix Technologies Inc.
Fig. 4 Cannabix “MS Breath Sampler” technology coupled with Thermo TSQ Ultra
2024 GlobeNewswire, Inc., source